Dong-A Pharm signs agreement with Novartis Korea for exclusive sales right for Exelon

Published: 2004-01-09 07:00:00

Updated: 2004-01-09 07:00:00

Dong-A Pharm said on January 6 that it signed a letter of intent with Novartis Korea, a Korean unit of Switzerland-based multinational pharmaceutical firm, for exclusive sales in Korea of Exelon (rivastigmine) which have been indicated for the treatment of Alzheimer's Disease (AD). The drug was i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK